NCT05748587View on ClinicalTrials.gov

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

CompletedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

April 1, 2024

Conditions
Brain Ischemia
Interventions
DIAGNOSTIC_TEST

Serum Iron

Serum iron levels in study groups

DIAGNOSTIC_TEST

RBCs Alpha-synuclein

α-syn levels in RBCs

DIAGNOSTIC_TEST

Serum Soluble lymphocyte activation gene

sLAG-3 in the serum of study groups

RADIATION

Brain computed tomography

Brain CT of patients after admission

DIAGNOSTIC_TEST

Brain Iron

Iron in brain homogenate of rats

DIAGNOSTIC_TEST

Brain Alpha-synuclein

α-syn expression in rat's brain

DIAGNOSTIC_TEST

Brain lymphocyte activation gene

LAG-3 expression in rat's brain

DRUG

Deferoxamine

intramuscular deferoxamine (200 mg/kg) injection to rats

Trial Locations (1)

81528

Aswan University Hospital, Aswān

All Listed Sponsors
lead

Aswan University Hospital

OTHER